Sign in
Not yet recruitingNo phase

Safflower (Carthamus Tinctorius L.) Granules for Sepsis-associated Coagulopathy

Key facts

Who runs it
Shanghai Jiao Tong University School of Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
210 people, planned
Started
1 Nov 2026
Expected to end
31 Aug 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • High-dose safflower granules
  • Medium-dose safflower granules
  • Placebo granules (one-tenth of medium-dose safflower)
Record updated
27 October 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age >= 18 and <= 80 years at admission
  • Meeting the Sepsis 3.0 diagnostic criteria, defined as infection-induced organ dysfunction with an increase in the Sequential Organ Failure Assessment (SOFA) score of >= 2 points from baseline
  • Coagulopathy at admission, defined as fibrin degradation products (FDP) > 9.9 mg/L AND D-dimer > 3.3 mg/L
  • Written informed consent obtained from the patient or legal representative

Who cannot take part

  • Current treatment with anticoagulant or antiplatelet agents for underlying conditions before admission
  • Requirement for any form of blood purification therapy or extracorporeal membrane oxygenation (due to mandatory anticoagulation)
  • Known allergy or hypersensitivity to Carthamus tinctorius L. (safflower)
  • Hematological disorders, autoimmune diseases, or advanced malignancy
  • Confirmed venous thromboembolism
  • Conditions with potential bleeding risk, including severe traumatic brain injury, cerebral aneurysm, arteriovenous malformation, bronchiectasis, or gastrointestinal ulcer; or within 24 hours of severe trauma or major surgery
  • Pre-existing chronic organ failure: cardiac failure (long-term left ventricular assist device or inotropic agents); hepatic failure (Child-Pugh class C); chronic respiratory failure (long-term home oxygen or non-invasive ventilation); chronic renal failure (glomerular filtration rate < 30 mL/min/1.73m2, or regular hemodialysis)
  • Pregnant or lactating women
  • Life expectancy < 48 hours
  • Participation in other interventional clinical trials within the study period

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sepsis is a life-threatening condition in which infection triggers widespread inflammation and blood clotting abnormalities. Many patients with sepsis develop coagulopathy (impaired blood clotting), which contributes to organ damage and death. Safflower (Carthamus tinctorius L.) is a traditional Chinese medicine herb with documented anticoagulant, anti-platelet, and blood vessel-protective properties. This randomized, double-blind, placebo-controlled trial will enroll 210 adult patients with sepsis-associated coagulopathy at Ruijin Hospital. Participants will be randomly assigned to one of three groups: high-dose safflower granules (equivalent to 9 g of raw herb daily), medium-dose safflower granules (equivalent to 6 g of raw herb daily), matching placebo (equivalent to 0.6 g of raw herb daily for blinding). The granules are dissolved in 50 mL of warm water and given through a nasogastric tube once daily for 7 days, in addition to standard sepsis treatment. The primary outcome is the improvement in the SOFA score (a measure of organ function) at 14 days. Secondary outcomes include DIC scores, coagulation tests, endothelial injury and platelet markers, inflammatory markers, 28-day mortality, length of ICU and hospital stay, and adverse events. The study is funded by Ruijin Hospital as an investigator-initiated trial.

The 3 groups in the trial

  • High-Dose SafflowerTreatment being tested

    Safflower (Carthamus tinctorius L.) granules equivalent to 9 g of raw herb, dissolved in 50 mL of warm water and given via nasogastric tube once daily for 7 consecutive days or until clinical stabilization, plus standard-of-care sepsis treatment.

    Treatment: High-dose safflower granules

  • Medium-Dose SafflowerTreatment being tested

    Safflower (Carthamus tinctorius L.) granules equivalent to 6 g of raw herb, dissolved in 50 mL of warm water and given via nasogastric tube once daily for 7 consecutive days or until clinical stabilization, plus standard-of-care sepsis treatment.

    Treatment: Medium-dose safflower granules

  • Placebo granules (one-tenth of medium-dose safflower)Placebo, for comparison

    Safflower (Carthamus tinctorius L.) granules at one-tenth of the medium dose (equivalent to 0.6 g of raw herb), dissolved in 50 mL of warm water and given via nasogastric tube once daily, same duration as the safflower groups, plus standard-of-care sepsis treatment. The one-tenth dose serves blinding by matching the appearance and odor of the study granules.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Safflower (Carthamus Tinctorius L.) Granules in Patients With Sepsis-associated Coagulopathy: a Randomized, Double-blind, Controlled, Three-arm Trial
Criteria questions
Built from NCT07897006, who can take part
Record updated
27 October 2026